Table 5. Clinical outcome.
| Dose level | n | Best response | Time on study (months) |
|---|---|---|---|
| 1 | 8a | PR (5) | 22, 26, 13, 37, 20 |
| SD (3) | 6, 5, 4 | ||
| 2 | 3a | PR (1) | 4 |
| SD (2) | 5, 4 | ||
| 4 | 2a | PR (1) | 26 |
| SD (1) | 5 | ||
| 1(uterine) | SD (1) | 4 | |
| 1(br) | SD (1) | 4 | |
| 1(bcc) | SD (1) | 4 | |
| 5a | 1a | SD (1) | 8 |
| 1 | SD (1) | 9 | |
| 5b | 1a | PR (1) | 8 |
| 2 (cx) | SD (2) | 5, 7 |
| All ovarian cancer (N=19; all DLs) | Intermittent sorafenib (DL 4, 5A, 5B; N=17) |
|---|---|
| PR 8/19=42% | PR 2/17 (12%) |
| PR or SD⩾ 4 cycles; 15/19=79% | PR or SD⩾ 4 cycles; 10/17 (59%) |
cx=cervical cancer; bcc=basal cell cancer; br=breast cancer; PR=partial response; SD=stable disease;
a
ovarian cancer.
SD other (1 each): melanoma, sarcoma, urothelial cancer.